Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2018

  • ID: 4583876
  • Drug Pipelines
  • 1759 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • BioCancell Ltd
  • Erytech Pharma SA
  • Juno Therapeutics Inc
  • Noxopharm Ltd
  • Rgenix Inc
  • MORE
Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2018, provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape.

Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells within the brain. Symptoms include headaches, blurred vision, nausea, vomiting, memory loss, speech difficulty, muscle weakness and loss of appetite. Risk factors include gender (male) and age. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights:

This latest pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glioblastoma Multiforme (GBM) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 10, 108, 67, 1, 9, 160, 28 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 11, 15, 1, 43 and 10 molecules, respectively.

Glioblastoma Multiforme (GBM) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Glioblastoma Multiforme (GBM) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Glioblastoma Multiforme (GBM) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • BioCancell Ltd
  • Erytech Pharma SA
  • Juno Therapeutics Inc
  • Noxopharm Ltd
  • Rgenix Inc
  • MORE
Introduction

Glioblastoma Multiforme (GBM) - Overview

Glioblastoma Multiforme (GBM) - Therapeutics Development

Glioblastoma Multiforme (GBM) - Therapeutics Assessment

Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development

Glioblastoma Multiforme (GBM) - Drug Profiles

Glioblastoma Multiforme (GBM) - Dormant Projects 1

Glioblastoma Multiforme (GBM) - Discontinued Products 1

Glioblastoma Multiforme (GBM) - Product Development Milestones 1

Appendix 1

List of Tables

Number of Products under Development for Glioblastoma Multiforme (GBM), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..8), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..9), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..10), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..11), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..12), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..13), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..14), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Products under Development by Companies, H1 2018 (Contd..8), H1 2018

Products under Development by Companies, H1 2018 (Contd..9), H1 2018

Products under Development by Companies, H1 2018 (Contd..10), H1 2018

Products under Development by Companies, H1 2018 (Contd..11), H1 2018

Products under Development by Companies, H1 2018 (Contd..12), H1 2018

Products under Development by Companies, H1 2018 (Contd..13), H1 2018

Products under Development by Companies, H1 2018 (Contd..14), H1 2018

Products under Development by Companies, H1 2018 (Contd..15), H1 2018

Products under Development by Companies, H1 2018 (Contd..16), H1 2018

Products under Development by Companies, H1 2018 (Contd..17), H1 2018

Products under Development by Companies, H1 2018 (Contd..18), H1 2018

Products under Development by Companies, H1 2018 (Contd..19), H1 2018

Products under Development by Companies, H1 2018 (Contd..20), H1 2018

Products under Development by Companies, H1 2018 (Contd..21), H1 2018

Products under Development by Universities/Institutes, H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..2), H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..3), H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..4), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..5), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..6), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..7), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..8), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..9), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..4), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..5), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..6), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..7), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..8), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..9), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Glioblastoma Multiforme (GBM) - Pipeline by AbbVie Inc, H1 2018

Glioblastoma Multiforme (GBM) - Pipeline by Actuate Therapeutics Inc, H1 2018

Glioblastoma Multiforme (GBM) - Pipeline by Aduro BioTech Inc, H1 2018

Glioblastoma Multiforme (GBM) - Pipeline by Advantagene Inc, H1 2018

Glioblastoma Multiforme (GBM) - Pipeline by Advenchen Laboratories LLC, H1 2018

Glioblastoma Multiforme (GBM) - Pipeline by Agenus Inc, H1 2018

List of Figures

Number of Products under Development for Glioblastoma Multiforme (GBM), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie Inc
  • Actuate Therapeutics Inc
  • Aduro BioTech Inc
  • Advantagene Inc
  • Advenchen Laboratories LLC
  • Agenus Inc
  • Ambrx Inc
  • Amgen Inc
  • Ampio Pharmaceuticals Inc
  • AngioChem Inc
  • Apac Biotech Pvt Ltd
  • apceth Biopharma GmbH
  • Apexigen Inc
  • APIM Therapeutics AS
  • Apogenix AG
  • Ariad Pharmaceuticals Inc
  • Arog Pharmaceuticals Inc
  • Arrien Pharmaceuticals LLC
  • Arrogene Inc
  • Astellas Pharma Inc
  • AstraZenecaPlc
  • Athenex Inc
  • Basilea Pharmaceutica Ltd
  • Batu Biologics Inc
  • Bayer AG
  • Beactica AB
  • BeiGene Ltd
  • Berg LLC
  • Bexion Pharmaceuticals LLC
  • BeyondSpring Pharmaceuticals Inc
  • Bio-Path Holdings Inc
  • Bioasis Technologies Inc
  • BioCancell Ltd
  • Biovista Inc
  • Boehringer Ingelheim GmbH
  • Boston Biomedical Inc
  • Bristol-Myers Squibb Co
  • Caladrius Biosciences Inc
  • Cantex Pharmaceuticals Inc
  • CARsgen Therapeutics Ltd
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Cellestia Biotech AG
  • Cellmid Ltd
  • Celsion Corp
  • ChemoCentryx Inc
  • Coherus BioSciences Inc
  • Cotinga Pharmaceuticals Inc
  • Curtana Pharmaceuticals Inc
  • Cynata Therapeutics Ltd
  • CytoVac AS
  • Daiichi Sankyo Co Ltd
  • Deciphera Pharmaceuticals LLC
  • DEKK-TEC Inc
  • DelMar Pharmaceuticals Inc
  • Diffusion Pharmaceuticals Inc
  • DNAtrix Inc
  • Dr. Reddy's Laboratories Ltd
  • Ecrins Therapeutics SAS
  • Eisai Co Ltd
  • Eli Lilly and Co
  • EnGeneIC Ltd
  • Enterome Bioscience SA
  • EntreChem SL
  • ERC Belgium SA
  • Erytech Pharma SA
  • Evotec AG
  • F-star Biotechnology Ltd
  • F. Hoffmann-La Roche Ltd
  • Falcon Therapeutics Inc
  • FirstString Research Inc
  • Fujifilm Holdings Corporation
  • Gene Techno Science Co Ltd
  • Genentech Inc
  • Genexine Inc
  • Genisphere LLC
  • GlaxoSmithKline Plc
  • GlioPharma ApS
  • GtreeBNT Co Ltd
  • GW Pharmaceuticals Plc
  • Hamlet Pharma AB
  • Hanmi Pharmaceuticals Co Ltd
  • Humanigen Inc
  • Hutchison MediPharma Ltd
  • Immatics Biotechnologies GmbH
  • ImmunoCellular Therapeutics Ltd
  • Immunomedics Inc
  • Immunomet Therapeutics Inc
  • Immunomic Therapeutics Inc
  • IMV Inc
  • Incyte Corp
  • Innovation Pharmaceuticals Inc
  • Inovio Pharmaceuticals Inc
  • Inspyr Therapeutics Inc
  • Instituto Biomar SA
  • Insys Therapeutics Inc
  • Iovance Biotherapeutics Inc
  • Ipsen SA
  • ISA Pharmaceuticals BV
  • Janpix Inc
  • JHL Biotech Inc
  • Jiangsu Kanion Pharmaceutical Co Ltd
  • Johnson & Johnson
  • Juno Therapeutics Inc
  • Kadmon Corp LLC
  • Kancera AB
  • Karyopharm Therapeutics Inc
  • Kazia Therapeutics Ltd
  • Kite Pharma Inc
  • Komipharm International Co Ltd
  • Kringle Pharma Inc
  • Kyorin Pharmaceutical Co Ltd
  • Les Laboratoires Servier SAS
  • Lin Bioscience Inc
  • Lixte Biotechnology Holdings Inc
  • Loxo Oncology Inc
  • Machavert Pharmaceuticals LLC
  • MacroGenics Inc
  • Medesis Pharma SA
  • Medicenna Therapeutics Corp
  • MedImmune LLC
  • MELEMA Pharma GmbH
  • Merck & Co Inc
  • Merck KGaA
  • MetaMax Ltd
  • Midatech Pharma Plc
  • Millennium Pharmaceuticals Inc
  • MimiVax LLC
  • Molecular Templates Inc
  • Moleculin Biotech LLC
  • Mycenax Biotech Inc
  • NanoCarrier Co Ltd
  • Nanomerics Ltd
  • NantKwest Inc
  • Nektar Therapeutics
  • Neonc Technologies Inc
  • Nerviano Medical Sciences Srl
  • NewLink Genetics Corp
  • Northwest Biotherapeutics Inc
  • Novartis AG
  • Noxopharm Ltd
  • Noxxon Pharma AG
  • Nuo Therapeutics Inc
  • NuvOx Pharma LLC
  • Omniox Inc
  • Oncobiologics Inc
  • Oncodesign SA
  • Oncolytics Biotech Inc
  • Onconova Therapeutics Inc
  • OncoResponse Inc
  • Oncternal Therapeutics Inc
  • Ono Pharmaceutical Co Ltd
  • Ovensa Inc
  • Patrys Ltd
  • Peloton Therapeutics Inc
  • Peptomyc SL
  • Pfizer Inc
  • Pharma Mar SA
  • PharmAbcine Inc
  • Pharmicell Co Ltd
  • Phoenix Biotechnology Inc
  • Plex Pharmaceuticals Inc
  • Prana Biotechnology Ltd
  • Protheragen Inc
  • PTC Therapeutics Inc
  • Puma Biotechnology Inc
  • Regeneron Pharmaceuticals Inc
  • Regulus Therapeutics Inc
  • ReNeuron Group Plc
  • Rgenix Inc
  • Richter Gedeon Nyrt
  • Sanofi
  • Sapience Therapeutics Inc
  • Scancell Holdings Plc
  • Scancell Ltd
  • SELLAS Life Sciences Group Inc
  • SignalChem Lifesciences Corp
  • SignPath Pharma Inc
  • Silenseed Ltd
  • StemGen SpA
  • Stemline Therapeutics Inc
  • Sumitomo Dainippon Pharma Co Ltd
  • Sun Pharma Advanced Research Company Ltd
  • Sunesis Pharmaceuticals Inc
  • Susavion Biosciences Inc
  • Symphogen A/S
  • Synactix Pharmaceuticals Inc
  • Systimmune Inc
  • Taiho Pharmaceutical Co Ltd
  • Terpenoid Therapeutics Inc
  • TheraBiologics Inc
  • Theralase Technologies Inc
  • Therapeia GmbH & Co KG
  • Tocagen Inc
  • TRACON Pharmaceuticals Inc
  • Transgene SA
  • Trillium Therapeutics Inc
  • Tyme Technologies Inc
  • Upsher-Smith Laboratories Inc
  • Vascular Biogenics Ltd
  • Vault Pharma Inc
  • Vaximm AG
  • VBI Vaccines Inc
  • VCN Biosciences SL
  • ViraTherapeutics GmbH
  • X4 Pharmaceuticals Inc
  • Xintela AB
  • Yooyoung Pharm Co Ltd
  • ZIOPHARM Oncology Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll